By: Benzinga
UPDATE: JP Morgan Downgrades Underweight on Myriad Genetics on Risk/Reward
JP Morgan reduced its rating on Myriad Genetics (NASDAQ: MYGN ) from Neutral to Underweight while reiterating its $26 price target. JP Morgan commented, "We see the investor debate in 2013 for Myriad Genetics (MYGN) as being
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here